Avalyn Pharma announced it will present two studies at the American Thoracic Society 2026 conference, focusing on patient experiences with its inhaled therapy AP01 and supportive care in pulmonary fibrosis. The presentations highlight Avalyn's commitment to incorporating patient and caregiver feedback to improve treatment usability and healthcare support. These findings support Avalyn's ongoing clinical trials of inhaled antifibrotic drugs aimed at improving lung function and reducing side effects in pulmonary fibrosis patients. The company aims to set a new standard of care with its inhaled therapies targeting rare respiratory diseases.
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
Novee has introduced Agentic Fix, an enhancement to its AI penetration testing platform that automates the transition from identifying security vulnerabilities to deploying fixes. This tool generates detailed remediation guidance based on validated e...
